BHV 1500
Alternative Names: BHV-1500; Next-gen brentuximab vedotin - Biohaven PharmaceuticalLatest Information Update: 14 Feb 2024
Price :
$50 *
At a glance
- Originator Biohaven Pharmaceutical Holding Company
- Class Antineoplastics; Antiretrovirals; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies; Oligopeptides; Skin disorder therapies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hodgkin's disease
Most Recent Events
- 08 Jan 2024 Preclinical trials in Hodgkin's disease in USA (Parenteral) before January 2024
- 08 Jan 2024 Biohaven Pharmaceutical Holding Company intends to file an IND application for Hodgkin's disease in 2H 2024
- 08 Jan 2024 Pharmacokinetics and pharmacodynamics data from a preclinical study in Hodgkin's disease released by Biohaven